Evelo Biosciences, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Other expenses
Loss on extinguishment of debt
Other miscellaneous income, net
Total other expenses, net

Loss before income taxes
Income tax expense
Net loss
Convertible preferred stock dividends
Net loss attributable to common stockholders
Unrealized gain on investments, net of tax of $0
Comprehensive loss
Weighted-average number of common shares outstanding, basic and diluted (in shares)
Net loss per share, basic and diluted (in dollars per share)
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)
Weighted average number of common shares outstanding, basic (in shares)
Weighted average number of common shares outstanding, diluted (in shares)

Comments